Unknown

Dataset Information

0

Daratumumab plus lenalidomide and dexamethasone versus lenalidomide and dexamethasone in relapsed or refractory multiple myeloma: updated analysis of POLLUX.


ABSTRACT: In the POLLUX study, daratumumab plus lenalidomide/dexamethasone significantly reduced risk of progression/death versus lenalidomide/dexamethasone alone in relapsed/refractory multiple myeloma. We provide one additional year of follow up and include the effect on minimal residual disease and in clinically relevant subgroups. After 25.4 months of follow up, daratumumab plus lenalidomide/dexamethasone prolonged progression-free survival versus lenalidomide/dexamethasone alone (median not reached vs 17.5 months; hazard ratio, 0.41; 95% confidence interval, 0.31-0.53; P<0.0001). The overall response rate was 92.9% versus 76.4%, and 51.2% versus 21.0% achieved a complete response or better, respectively (both P<0.0001). At the 10-5 sensitivity threshold, 26.2% versus 6.4% were minimal residual disease-negative, respectively (P<0.0001). Post hoc analyses of clinically relevant patient subgroups demonstrated that progression-free survival was significantly prolonged for daratumumab plus lenalidomide/dexamethasone versus lenalidomide/dexamethasone regardless of number of prior lines of therapy. Patients previously treated with lenalidomide or thalidomide and those refractory to bortezomib received similar benefits (all P<0.01). Treatment benefit with daratumumab plus lenalidomide/dexamethasone was maintained in high-risk patients (median progression-free survival 22.6 vs 10.2 months; hazard ratio, 0.53; 95% confidence interval, 0.25-1.13; P=0.0921) and patients with treatment-free intervals of >12 and ?12 months and >6 and ?6 months. No new safety signals were observed. In relapsed/refractory multiple myeloma patients, daratumumab plus lenalidomide/dexamethasone continued to improve progression-free survival and deepen responses versus lenalidomide/dexamethasone. Trial Registration: clinicaltrials.gov identifier: 02076009.

SUBMITTER: Dimopoulos MA 

PROVIDER: S-EPMC6269302 | biostudies-literature | 2018 Dec

REPOSITORIES: biostudies-literature

altmetric image

Publications

Daratumumab plus lenalidomide and dexamethasone <i>versus</i> lenalidomide and dexamethasone in relapsed or refractory multiple myeloma: updated analysis of POLLUX.

Dimopoulos Meletios A MA   San-Miguel Jesus J   Belch Andrew A   White Darrell D   Benboubker Lotfi L   Cook Gordon G   Leiba Merav M   Morton James J   Ho P Joy PJ   Kim Kihyun K   Takezako Naoki N   Moreau Philippe P   Kaufman Jonathan L JL   Sutherland Heather J HJ   Lalancette Marc M   Magen Hila H   Iida Shinsuke S   Kim Jin Seok JS   Prince H Miles HM   Cochrane Tara T   Oriol Albert A   Bahlis Nizar J NJ   Chari Ajai A   O'Rourke Lisa L   Wu Kaida K   Schecter Jordan M JM   Casneuf Tineke T   Chiu Christopher C   Soong David D   Sasser A Kate AK   Khokhar Nushmia Z NZ   Avet-Loiseau Hervé H   Usmani Saad Z SZ  

Haematologica 20180920 12


In the POLLUX study, daratumumab plus lenalidomide/dexamethasone significantly reduced risk of progression/death <i>versus</i> lenalidomide/dexamethasone alone in relapsed/refractory multiple myeloma. We provide one additional year of follow up and include the effect on minimal residual disease and in clinically relevant subgroups. After 25.4 months of follow up, daratumumab plus lenalidomide/dexamethasone prolonged progression-free survival <i>versus</i> lenalidomide/dexamethasone alone (median  ...[more]

Similar Datasets

| S-EPMC7643179 | biostudies-literature
| S-EPMC6269293 | biostudies-other
| S-EPMC7326710 | biostudies-literature
| S-EPMC7685974 | biostudies-literature
| S-EPMC5928154 | biostudies-literature
| S-EPMC5570682 | biostudies-literature
| S-EPMC10045721 | biostudies-literature
| S-EPMC6676132 | biostudies-literature
| S-EPMC10134287 | biostudies-literature
| S-EPMC7027539 | biostudies-literature